Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants (IDX)

This study has been completed.
Sponsor:
Collaborator:
Elizabeth Glaser Pediatric AIDS Foundation
Information provided by (Responsible Party):
Benjamin Chi, MD, MSc, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01222130
First received: October 14, 2010
Last updated: September 16, 2014
Last verified: September 2014
  Purpose

This study is designed to develop and evaluate a set of non-virologic diagnostic algorithms to monitor HIV-exposed children of unknown infection status for treatment eligibility during the first year of life. The results of this cross sectional study are expected to be used in development of a series of non-virologic algorithms to determining treatment eligibility among HIV-exposed children in settings where polymerase chain reaction (PCR) testing is not available and to guide the judicious use of PCR testing among HIV-exposed children in settings where PCR is available. These results will directly inform program implementation in Zambia.


Condition
HIV Infections

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: CIDRZ 1234 - Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants

Resource links provided by NLM:


Further study details as provided by University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • performance (i.e., sensitivity, specificity, negative and positive predictive value) of different algorithms in predicting virologically confirmed HIV infection [ Time Frame: within first 12 months of life ] [ Designated as safety issue: No ]

Enrollment: 1126
Study Start Date: July 2009
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Hide Detailed Description

Detailed Description:

Despite recent scientific advances in prevention of mother-to-child transmission (PMTCT), substantial donor investment, and national commitments to PMTCT program roll-out, pediatric HIV/AIDS remains a largely uncontrolled epidemic. Unless some intervention is undertaken, more than half of children who become HIV-infected will die by their second birthday. Yet in sub-Saharan Africa, the majority of infected children die without ever having confirmation of their HIV status, having never had the chance to begin life-saving antiretroviral therapy (ART). Recognizing the need to provide children with greater access to care, the World Health Organization (WHO) has advised countries that at least 10% of patients receiving ART should be children. However, most programs fall well short of this target.

Unlike diagnosis in adults, definitive diagnosis of HIV in children less than 18 months of age requires virologic testing. Maternal IgG antibodies cross the placenta into the fetal circulation through pregnancy and are also secreted in breast milk. As infants may retain these maternal antibodies for up to 18 months after birth, conventional HIV antibody tests are of limited use in determining positive infection status. Instead it is necessary to directly identify HIV infection using a virologic method, typically polymerase chain reaction (PCR) testing to detect viral DNA or RNA.

PCR testing is expensive and, in most developing countries, available only through specialty laboratories. Because PCR testing is more complex than other common HIV laboratory assays (e.g. CD4+ cell counting), it requires technicians with considerably more training and technical skill, involves longer sample preparation time, and can be considerably more costly than other diagnostic tests. Thus, most countries with large populations of HIV-infected children have extremely limited capacity to carry out PCR testing. Even where PCR is available, pediatric HIV diagnosis may remain difficult in breastfeeding populations because infants are at continued risk of infection until breastfeeding is completely stopped. A negative PCR test during breastfeeding does not guarantee that the infant will remain uninfected. The alternative - serial testing for HIV infection - would result in an exponential increase in cost.

Indeed, a convincing argument can be made that rather than monitoring HIV-exposed breastfeeding children for HIV infection, it may be more appropriate to simply monitor for treatment eligibility, followed by a definitive antibody test at 15-18 months or a few months after breastfeeding has stopped. Those children who meet criteria for treatment could be commenced on ART; those who do not would continue to undergo periodic screening until they were weaned and old enough to have a final (definitive) antibody test. For HIV-exposed infants without access to HIV PCR testing - the vast majority in Africa - development of such an algorithm would have the obvious benefit of providing reliable evaluation for treatment eligibility in the first 18 months of life. Even in settings where HIV PCR testing is available - but may be limited - the introduction of such algorithms could reduce the volume of HIV PCR tests required at a programmatic level, and thus lead to substantial cost-savings.

The overall goal of this protocol is to develop and evaluate a set of non-virologic diagnostic algorithms that can be used to monitor HIV-exposed children of unknown infection status for treatment eligibility during the first 12 weeks of life, with validation of our model among HIV-exposed children up to 12 months of age. We will evaluate the performance of different algorithms in two separate but common scenarios in Africa: (1) where infant PCR testing is not available, and (2) where infant PCR may be available, but poorly accessible due to cost and resource considerations. Although DNA PCR testing has become available in Zambia, only three sites currently provide this type of testing and capacity may be limited for country-wide screening. Our study was designed to determine HIV infection and antiretroviral therapy (ART) eligibility using more commonly used "non-virologic" tests, such as CD4, CD8, HIV antibody, total lymphocyte count, hemoglobin, and clinical staging. Previous studies have demonstrated that these indicators by themselves do not perform well in the absence of DNA PCR testing. In this exploratory study, we hypothesize that combinations of these tests - in formalized algorithms - can yield high performance and be used in rural settings where reliable DNA PCR services are not yet available or remain limited.

  Eligibility

Ages Eligible for Study:   up to 60 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

HIV-infected mothers and their exposed infants seek care in a primary care setting in Lusaka, Zambia

Criteria

Inclusion Criteria:

  • mother with documented HIV infections
  • mother willing to give informed consent for participation
  • mother willing to allow child to participant in the study
  • infant equal or less than 60 weeks of age

Exclusion Criteria:

  • infants accompanied by someone other than the mother
  • infants already received antiretroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01222130

Locations
Zambia
George Health Centre
Lusaka, Zambia, 10101
Kamwala Health Centre
Lusaka, Zambia, 10101
Matero Reference Health Centre
Lusaka, Zambia, 10101
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Elizabeth Glaser Pediatric AIDS Foundation
  More Information

No publications provided

Responsible Party: Benjamin Chi, MD, MSc, Associate Professor, University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT01222130     History of Changes
Other Study ID Numbers: MQ-00-6-300-01206-0-00
Study First Received: October 14, 2010
Last Updated: September 16, 2014
Health Authority: Zambia: Ministry of Health

Keywords provided by University of North Carolina, Chapel Hill:
HIV
Infant infection
Diagnosis
Non-virological algorithm

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Infection
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on November 24, 2014